WALTHAM, Mass • 2022-05-10

BostonGene Announces Integration With NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

5 min to read

The Inclusion of NCCN Guidelines® Into the BostonGene Tumor Portrait™ Test Report Allows Physicians Real-Time Access to Evidenced-Based Care for Cancer Patients
WALTHAM, Mass. – May 10, 2022

BostonGene today announced a strategic agreement with the National Comprehensive Cancer Network® (NCCN®) to integrate its Clinical Practice Guidelines into the BostonGene Tumor PortraitTM Test reports.

The NCCN Guidelines® are comprehensive, evidence-based recommendations for the prevention, diagnosis, and management of cancer.  Applicable to over 97% of malignancies affecting patients in the United States, the NCCN Guidelines assist physicians, nurses, payers, patients, and families in cancer care decision-making.

The BostonGene Tumor Portrait™ Test uses DNA whole exome (WES) and RNA transcriptome (RNAseq) sequencing to analyze the tumor and its surrounding stroma, revealing critical drivers of each tumor, including immune microenvironment properties, actionable mutations, and biomarkers of response, and link findings to recommended management. By integrating genomic and transcriptomic analysis, in concert with the patient’s clinical history, the BostonGene Tumor Portrait™ Test provides information regarding biomarkers associated with response/resistance to therapies or therapeutic combinations, NCCN Guidelines treatment recommendations, and ongoing clinical trials.

“Combining BostonGene's genomic and transcriptomic analysis with the NCCN Guidelines creates a significant opportunity to provide evidence-based care for cancer patients,” said Nathan Fowler, MD, Chief Medical Officer at BostonGene. “We are pleased to be working with NCCN to further strengthen the BostonGene Tumor PortraitTM Test report and provide additional decision-making information to physicians.”

“NCCN is committed to maintaining clinical practice guidelines that include actionable biomarkers and recommendations for cancer treatment options based upon biomarker results. We are pleased that BostonGene will be utilizing the NCCN Guidelines to generate reports linking biomarker results with evidence-based treatment recommendations,” said Robert W. Carlson, MD, Chief Executive Officer at NCCN.


About NCCN

The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, equitable, and accessible cancer care so all patients can live better lives. Visit NCCN.org for more information on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and other initiatives. Follow NCCN on Facebook @NCCNorg, Instagram @NCCNorg and Twitter @NCCN.

About BostonGene Corporation

BostonGene has a mission to provide transformative, AI-integrated molecular analytics and biomarker discovery for precision matching of therapies to improve the lives of patients living with cancer and other immune-related diseases. BostonGene’s service model provides customized client solutions using a multi-omic approach prioritized for real-world impact, including optimized standard-of-care therapies, accelerated research and cost-effective, measurable results. BostonGene’s tests reveal key drivers of each patient’s unique disease profile, including an in-depth profile of the immune microenvironment, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene’s tests generate a personalized roadmap for therapeutic decision-making for each patient. For more information, visit BostonGene at http://www.BostonGene.com.

Erin O’Reilly

Senior Director